Obefazimod Induction Treatment for Ulcerative Colitis

Obefazimod Induction Treatment for Ulcerative Colitis
90%69%48%Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 26 • YES 55.0%Apr 27 • YES 67.0%Apr 28 • YES 67.0%Apr 29 • YES 67.0%Apr 30 • YES 67.0%May 1 • YES 67.0%May 2 • YES 67.0%May 3 • YES 67.0%May 4 • YES 67.0%May 5 • YES 67.0%May 6 • YES 55.4%May 7 • YES 61.5%May 9 • YES 65.5%May 11 • YES 77.5%May 12 • YES 82.5%May 13 • YES 82.9%
Abivax S.A. ($ABVX)
No stock closeNo stock close$129.8$116.4$103.0Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 27 • ABVX $111.9Apr 28 • ABVX $109.9Apr 29 • ABVX $106.2Apr 30 • ABVX $117.4May 1 • ABVX $117.6May 4 • ABVX $117.1May 5 • ABVX $123.8May 6 • ABVX $126.5May 7 • ABVX $124.7May 8 • ABVX $122.7May 11 • ABVX $122.1May 12 • ABVX $121.4May 13 • ABVX $121.9

Will this trial show a positive result on clinical remission at 8 weeks based on the Modified Mayo Score?

Paper Trading
Create account to trade
ClinicalTrialModel PositionsModel ReasoningOracle
Primary Completion
6/24/25
Study Completion
6/25/25
Sponsor
Abivax S.A.
Ticker
$ABVX
Type
Phase 3
Trial Status
Completed
Trial Size
639
NCT
NCT05507203
Trial Description
This trial tested once-daily obefazimod in people with moderately to severely active ulcerative colitis, measuring clinical remission after 8 weeks.